Cargando…

A longitudinal study of risk factors for community-based home help services in Alzheimer’s disease: the influence of cholinesterase inhibitor therapy

BACKGROUND: To investigate the long-term effects of cholinesterase inhibitor (ChEI) therapy and the influence of sociodemographic and clinical factors on the use of community-based home help services (HHS) by patients with Alzheimer’s disease (AD). METHODS: This 3-year, prospective, multicenter stud...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wattmo, Carina, Paulsson, Elisabeth, Minthon, Lennart, Londos, Elisabet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3610439/ https://www.ncbi.nlm.nih.gov/pubmed/23682212 http://dx.doi.org/10.2147/CIA.S40087

Ejemplares similares

Short-Term Response to Cholinesterase Inhibitors in Alzheimer’s Disease Delays Time to Nursing Home Placement
por: Wattmo, Carina, et al.
Publicado: (2018)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer’s disease: a prospective, observational study of factors affecting survival time from admission to death
por: Wattmo, Carina, et al.
Publicado: (2016)

Solitary living in Alzheimer’s disease over 3 years: association between cognitive and functional impairment and community-based services
por: Wattmo, Carina, et al.
Publicado: (2014)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Predictors of long-term cognitive outcome in Alzheimer's disease
por: Wattmo, Carina, et al.
Publicado: (2011)

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2016)

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2010)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies
por: Wattmo, Carina, et al.
Publicado: (2013)

Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting
por: Wallin, Åsa K, et al.
Publicado: (2011)

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden
por: Zahirovic, Iris, et al.
Publicado: (2018)

Survival among the older adults with clinical signs of Lewy body dementia in 40 Swedish nursing homes: a 6-year follow-up study
por: Zahirovic, Iris, et al.
Publicado: (2019)

Reliability, validity and clinical correlates of the Quality of Life in Alzheimer’s disease (QoL-AD) scale in medical inpatients
por: Torisson, Gustav, et al.
Publicado: (2016)

A Longitudinal Study of Physical Function in Patients with Early-Onset Dementia
por: Tangen, Gro Gujord, et al.
Publicado: (2012)

Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2014)

The Impact of Autonomic Dysfunction on Survival in Patients with Dementia with Lewy Bodies and Parkinson's Disease with Dementia
por: Stubendorff, Kajsa, et al.
Publicado: (2012)

Multidisciplinary intervention reducing readmissions in medical inpatients: a prospective, non-randomized study
por: Torisson, Gustav, et al.
Publicado: (2013)

Cognitive impairment is undetected in medical inpatients: a study of mortality and recognition amongst healthcare professionals
por: Torisson, Gustav, et al.
Publicado: (2012)

Importance and added value of functional impairment to predict mortality: a cohort study in Swedish medical inpatients
por: Torisson, Gustav, et al.
Publicado: (2017)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Medial temporal lobe atrophy is underreported and may have important clinical correlates in medical inpatients
por: Torisson, Gustav, et al.
Publicado: (2015)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
por: Wennström, Malin, et al.
Publicado: (2015)

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study
por: Stubendorff, Kajsa, et al.
Publicado: (2014)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Early-versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression
por: Wattmo, Carina, et al.
Publicado: (2017)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

OUTCOMES OF DISCONTINUING CHOLINESTERASE INHIBITORS IN NURSING HOME RESIDENTS WITH SEVERE DEMENTIA
por: Niznik, Joshua D, et al.
Publicado: (2019)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

A new automated method for analysis of rCBF-SPECT images based on the active-shape algorithm: normal values
por: Hägerström, Douglas, et al.
Publicado: (2012)

Early- versus late-onset Alzheimer’s disease in clinical practice: cognitive and global outcomes over 3 years
por: Wattmo, Carina, et al.
Publicado: (2017)

A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
por: S. Schneider, Lon
Publicado: (2000)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_g9bko0p7cfq48nv56em7br85q7